Coordination chemistry and biology of chelators for the treatment of iron overload disorders.
Treatment of the medical condition generally referred to as iron overload through the delivery of chelators has recently received a major boost. In 2005 Novartis gained FDA approval for the drug deferasirox, which may be taken orally. Until this time most patients with Fe overload have had to endure long periods of subcutaneous infusions of the orally ineffective drug desferrioxamine (desferal) which has led to major problems with patient compliance. An effective Fe chelator must possess a number of properties for it to be able to complex Fe in vivo and be excreted intact. This Perspective will provide an overview of the current state of chelators for Fe overload; both those currently approved and those undergoing preclinical development.
Bernhardt
Paul V
PV
Centre for Metals in Biology, Department of Chemistry, University of Queensland, Brisbane, 4072, Australia. P.Bernhardt@uq.edu.au
D001565:Benzoates / Q000737:chemistry; D002626:Chemistry, Pharmaceutical; D018360:Crystallography, X-Ray; D000077588:Deferasirox; D000077543:Deferiprone; D003676:Deferoxamine / Q000737:chemistry; D005290:Ferric Compounds / Q000737:chemistry; D006801:Humans; D007502:Iron Chelating Agents / Q000737:chemistry* / Q000627:therapeutic use; D019190:Iron Overload / Q000188:drug therapy*; D008958:Models, Molecular; D011728:Pyridones / Q000737:chemistry; D014230:Triazoles / Q000737:chemistry
D001565:Benzoates; D005290:Ferric Compounds; D007502:Iron Chelating Agents; D011728:Pyridones; D014230:Triazoles; D000077543:Deferiprone; C002577:ferrioxamine B; D003676:Deferoxamine; D000077588:Deferasirox